Clinicopathologic Features of Operated Gastrointestinal Stromal Tumors, Adjuvant Therapy Outcomes, and Recurrence-Related Factors

Abstract

Objectives: We aimed to evaluate the clinicopathological features and clinical outcomes of patients with resected\rGastrointestinal stromal tumors (GISTs).\rMethods: This study was a retrospective, multicenter cohort study. Patients diagnosed with a GIST, 18 years of age and\rolder, operated on R0, between January 2005 and May 2020 were included in the study. Patient with metastatic disease\rat diagnosis were excluded.\rResults: Of 104 patients, the median age was 61 years (35-87) and 58.7% (n=61) were male. The most common location\rwas stomach (n=52.5%). According to The Modified-National Institutes of Health (M-NIH) classifications, 52 (50%) patients\rwere in the high-risk group. The median relapse-free survival (RFS) was 62.1 (95% CI; 52.7-71.5) months. Increased\raged at diagnosis (HR=0.952, 95% CI 0.910-0.995, p=0.030), Ki-67<10% (HR=5.007, 95% CI 1.503-16.680, p=0.009), low\rrisk M-NIH category (HR=21,083, 95% CI 2.119-209.769, p=0.009), two-year adjuvant imatinib (HR= 0.255, 95% CI 0.070-\r0.920, p=0.037) or three-year treatment (HR=0.191 95% CI 0.040-0.919, p=0.039) were independent factors for RFS.\rConclusion: High ki-67 index and high M-NIH score are factors that have a negative effect on relapse. Keeping the\radjuvant treatment period longer than one year and advanced age have a positive effect on recurrence.